Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLINI: Pre-operative phase II trial for breast cancer with nivolumab in combination with novel immuno-oncology agents
2024-515080-54-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of nivolumab in breast cancer, triple-negative breast cancer (TNBC) and Luminal B breast cancer (8 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Pathological complete response rate per cohort. Planned start Dec 2024; status: authorised.
02
Drugs
03
Conditions
breast cancertriple-negative breast cancer (TNBC)Luminal B breast cancer
Beyond the preview
Go deeper on 2024-515080-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515080-54-00.